179 related articles for article (PubMed ID: 12056903)
21. Targeted genome modification via triple helix formation.
Kalish JM; Glazer PM
Ann N Y Acad Sci; 2005 Nov; 1058():151-61. PubMed ID: 16394134
[TBL] [Abstract][Full Text] [Related]
22. High-frequency intrachromosomal gene conversion induced by triplex-forming oligonucleotides microinjected into mouse cells.
Luo Z; Macris MA; Faruqi AF; Glazer PM
Proc Natl Acad Sci U S A; 2000 Aug; 97(16):9003-8. PubMed ID: 10900269
[TBL] [Abstract][Full Text] [Related]
23. Triplex targeted genomic crosslinks enter separable deletion and base substitution pathways.
Richards S; Liu ST; Majumdar A; Liu JL; Nairn RS; Bernier M; Maher V; Seidman MM
Nucleic Acids Res; 2005; 33(17):5382-93. PubMed ID: 16186129
[TBL] [Abstract][Full Text] [Related]
24. Gene targeting via triple-helix formation.
Casey BP; Glazer PM
Prog Nucleic Acid Res Mol Biol; 2001; 67():163-92. PubMed ID: 11525382
[TBL] [Abstract][Full Text] [Related]
25. Site-specific mutagenesis by triple helix-forming oligonucleotides containing a reactive nucleoside analog.
Nagatsugi F; Sasaki S; Miller PS; Seidman MM
Nucleic Acids Res; 2003 Mar; 31(6):e31. PubMed ID: 12626730
[TBL] [Abstract][Full Text] [Related]
26. Peptide conjugates for chromosomal gene targeting by triplex-forming oligonucleotides.
Rogers FA; Manoharan M; Rabinovitch P; Ward DC; Glazer PM
Nucleic Acids Res; 2004; 32(22):6595-604. PubMed ID: 15602001
[TBL] [Abstract][Full Text] [Related]
27. Improved bioactivity of G-rich triplex-forming oligonucleotides containing modified guanine bases.
Rogers FA; Lloyd JA; Tiwari MK
Artif DNA PNA XNA; 2014; 5(1):e27792. PubMed ID: 25483840
[TBL] [Abstract][Full Text] [Related]
28. Transplatin-conjugated triplex-forming oligonucleotides form adducts with both strands of DNA.
Campbell MA; Miller PS
Bioconjug Chem; 2009 Dec; 20(12):2222-30. PubMed ID: 19950917
[TBL] [Abstract][Full Text] [Related]
29. Potassium-resistant triple helix formation and improved intracellular gene targeting by oligodeoxyribonucleotides containing 7-deazaxanthine.
Faruqi AF; Krawczyk SH; Matteucci MD; Glazer PM
Nucleic Acids Res; 1997 Feb; 25(3):633-40. PubMed ID: 9016606
[TBL] [Abstract][Full Text] [Related]
30. Binding of triple helix forming oligonucleotides to sites in gene promoters.
Durland RH; Kessler DJ; Gunnell S; Duvic M; Pettitt BM; Hogan ME
Biochemistry; 1991 Sep; 30(38):9246-55. PubMed ID: 1892832
[TBL] [Abstract][Full Text] [Related]
31. (A,G)-oligonucleotides form extraordinary stable triple helices with a critical R.Y sequence of the murine c-Ki-ras promoter and inhibit transcription in transfected NIH 3T3 cells.
Alunni-Fabbroni M; Pirulli D; Manzini G; Xodo LE
Biochemistry; 1996 Dec; 35(50):16361-9. PubMed ID: 8973212
[TBL] [Abstract][Full Text] [Related]
32. Chemical modification of triplex-forming oligonucleotide to promote pyrimidine motif triplex formation at physiological pH.
Torigoe H; Nakagawa O; Imanishi T; Obika S; Sasaki K
Biochimie; 2012 Apr; 94(4):1032-40. PubMed ID: 22245184
[TBL] [Abstract][Full Text] [Related]
33. Intercalator conjugates of pyrimidine locked nucleic acid-modified triplex-forming oligonucleotides: improving DNA binding properties and reaching cellular activities.
Brunet E; Corgnali M; Perrouault L; Roig V; Asseline U; Sørensen MD; Babu BR; Wengel J; Giovannangeli C
Nucleic Acids Res; 2005; 33(13):4223-34. PubMed ID: 16049028
[TBL] [Abstract][Full Text] [Related]
34. High-affinity triple helix formation by synthetic oligonucleotides at a site within a selectable mammalian gene.
Vasquez KM; Wensel TG; Hogan ME; Wilson JH
Biochemistry; 1995 May; 34(21):7243-51. PubMed ID: 7766635
[TBL] [Abstract][Full Text] [Related]
35. Triplex formation by psoralen-conjugated chimeric oligonucleoside methylphosphonates.
Cassidy RA; Kondo NS; Miller PS
Biochemistry; 2000 Jul; 39(29):8683-91. PubMed ID: 10913277
[TBL] [Abstract][Full Text] [Related]
36. Targeting bcl-2 by triplex-forming oligonucleotide--a promising carrier for gene-radiotherapy.
Shen C; Rattat D; Buck A; Mehrke G; Polat B; Ribbert H; Schirrmeister H; Mahren B; Matuschek C; Reske SN
Cancer Biother Radiopharm; 2003 Feb; 18(1):17-26. PubMed ID: 12667305
[TBL] [Abstract][Full Text] [Related]
37. Triplex-forming oligonucleotides as potential tools for modulation of gene expression.
Rogers FA; Lloyd JA; Glazer PM
Curr Med Chem Anticancer Agents; 2005 Jul; 5(4):319-26. PubMed ID: 16101484
[TBL] [Abstract][Full Text] [Related]
38. Triplex forming ability of oligonucleotides containing 2'-O-methyl-2-thiouridine or 2-thiothymidine.
Okamoto I; Seio K; Sekine M
Bioorg Med Chem Lett; 2006 Jun; 16(12):3334-6. PubMed ID: 16631365
[TBL] [Abstract][Full Text] [Related]
39. Targeted genome modification via triple helix formation.
Ricciardi AS; McNeer NA; Anandalingam KK; Saltzman WM; Glazer PM
Methods Mol Biol; 2014; 1176():89-106. PubMed ID: 25030921
[TBL] [Abstract][Full Text] [Related]
40. Targeted correction of an episomal gene in mammalian cells by a short DNA fragment tethered to a triplex-forming oligonucleotide.
Chan PP; Lin M; Faruqi AF; Powell J; Seidman MM; Glazer PM
J Biol Chem; 1999 Apr; 274(17):11541-8. PubMed ID: 10206960
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
